Amar U. Kishan, MD - Radiation Oncology ...

Dr. Amar Kishan

Claim this profile

UCLA / Jonsson Comprehensive Cancer Center

Studies Prostate Cancer
Studies Prostate Adenocarcinoma
10 reported clinical trials
12 drugs studied

Area of expertise

1

Prostate Cancer

Amar Kishan has run 9 trials for Prostate Cancer. Some of their research focus areas include:

Stage IV
Stage I
Stage II
2

Prostate Adenocarcinoma

Amar Kishan has run 8 trials for Prostate Adenocarcinoma. Some of their research focus areas include:

Stage IV
Stage I
Stage II

Affiliated Hospitals

Image of trial facility.

UCLA / Jonsson Comprehensive Cancer Center

Clinical Trials Amar Kishan is currently running

Image of trial facility.

Hormone + Radiation Therapy

for Prostate Cancer

This phase II trial evaluates apalutamide in combination with image-guided stereotactic body radiation therapy (SBRT) for the treatment of patients with prostate cancer. Prostate cancer usually needs the hormone testosterone to grow. Apalutamide is a hormone therapy that blocks the effect of testosterone on prostate tumor cells. This may help stop the growth of tumor cells that need testosterone to grow. Image-guided SBRT is a standard treatment for some types of prostate cancer. This treatment combines imaging of cancer within the body, with the delivery of therapeutic radiation doses produced on a linear accelerator machine. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Combining apalutamide with image-guided SBRT may increase a prostate cancer patient's chances of achieving an extremely low prostate specific antigen response, which is an early predictor of disease cure.

Recruiting

1 award

Phase 2

16 criteria

Image of trial facility.

Stereotactic Radiotherapy + Hormone Therapy

for Prostate Cancer

This phase II trial investigates the effect of extremely hypofractionated intensity modulated stereotactic body radiotherapy in treating patients with prostate cancer that has rising prostate specific antigen (PSA) after radical prostatectomy. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects.

Recruiting

1 award

Phase 2

More about Amar Kishan

Clinical Trial Related

7 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 4 Active Clinical Trials

Treatments Amar Kishan has experience with

  • Stereotactic Body Radiation Therapy
  • Apalutamide
  • Lutetium Lu-177 PNT2002
  • Hormone Therapy
  • Germline DNA-Based Radiosensitivity Biomarker
  • Hypofractionated Radiation Therapy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Amar Kishan specialize in?

Is Amar Kishan currently recruiting for clinical trials?

Are there any treatments that Amar Kishan has studied deeply?

What is the best way to schedule an appointment with Amar Kishan?

What is the office address of Amar Kishan?

Is there any support for travel costs?